Holen Sie sich die Stockscreener-App
25.32
3.51%
-0.92
Handel nachbörslich:
25.43
0.11
+0.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
RARE Maintained by Canaccord Genuity -- Price Target Raised to $83 - GuruFocus
Canaccord Genuity Group Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx scores FDA approval for gene therapy made at Bedford facility - The Business Journals
RARE Maintained by Citigroup -- Price Target Raised to $58.00 - GuruFocus
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease - MedCity News
GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing - PharmTech.com
RARE Maintained by Wells Fargo -- Price Target Raised to $46.00 - GuruFocus
Ultragenyx, after setbacks, nabs first gene therapy approval - BioPharma Dive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $46.00 Price Target at Wells Fargo & Company - MarketBeat
FDA Grants Accelerated Approval to Ultragenyx's Genglycos, First Gene Therapy for Glycogen Storage Disease Type Ia - BioPharm International
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up After Analyst Upgrade - MarketBeat
Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa - pharmaphorum
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos - TradingView
Ultragenyx Lands Genglycos Approval And Sets Its Sights On A PRV Double - insights.citeline.com
Ultragenyx's new therapy targets patients with a rare genetic disease. It costs $2.7 million. - The Business Journals
FDA approves Ultragenyx gene therapy - STAT
Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock - Yahoo Finance
Ultragenyx Nabs FDA Nod for First Gene Therapy - Benzinga
Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
H.C. Wainwright reiterates Ultragenyx stock rating at buy By Investing.com - Investing.com Canada
Canaccord raises Ultragenyx stock price target on FDA approval By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Ultragenyx stock rating at buy - Investing.com
Canaccord raises Ultragenyx stock price target on FDA approval - Investing.com
FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy - Pharmaceutical Business review -
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy - MarketBeat
RARE Maintained by Cantor Fitzgerald -- Price Target Raised to $103 - GuruFocus
Ultragenyx’ Genglycos wins FDA accelerated approval - The Pharma Letter
FDA approves Genglycos as first gene therapy for glycogen storage disease type Ia - AllSci
Eagle Health Investments LP Acquires Shares of 884,121 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx stock surges on FDA gene therapy approval - Investing.com
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - pharma.economictimes.indiatimes.com
Ultragenyx Earnings Call Signals Record Sales, 2027 Pivot - TipRanks
Ultragenyx gets its first gene therapy over the regulatory finish line - FirstWord Pharma
Ultragenyx’s gene therapy wins first FDA approval for rare metabolic disorder - 95.7 KELO-FM
RARE Stock Jumps 6% After-Hours On First Gene Therapy Approval, New Priority Review Voucher - Stocktwits
Ultragenyx receives FDA approval for gene therapy treating GSDIa By Investing.com - Investing.com Nigeria
Form 8K Ultragenyx For: 19 August By Investing.com - Investing.com Nigeria
Ultragenyx stock surges on FDA gene therapy approval By Investing.com - Investing.com Australia
Ultragenyx’s gene therapy for rare metabolic disorder secures US FDA nod - 1470 & 100.3 WMBD
RARE Looks 41.8% Undervalued on GF Value™ Amid Gene Therapy FDA Approval - GuruFocus
Ultragenyx receives FDA accelerated approval for gene therapy in GSDIa By Investing.com - Investing.com Canada
Ultragenyx receives FDA accelerated approval for gene therapy in GSDIa - Investing.com
Ultragenyx Pharmaceutical Receives Accelerated US FDA Approval for Genglycos - marketscreener.com
Ultragenyx wins accelerated approval of gene therapy for glycogen storage disease - Seeking Alpha
Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod - Yahoo
Ultragenyx Receives FDA Accelerated Approval for GENGLYCOS Gene Therapy for GSDIa - Quiver Quantitative
Ultragenyx receives FDA approval for gene therapy treating GSDIa - Investing.com
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene - GlobeNewswire
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) - Yahoo Finance Singapore
Ultragenyx (RARE) Stock Could Stay Fully Priced On Setrusumab Regulatory Talks - simplywall.st
Bank of America Corp DE Has $21.93 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy - Stocktwits
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Piper Sandler Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $68 - Moomoo
Ultragenyx Pharmaceutical Inc. Revenue Breakdown – NASDAQ:RARE - TradingView
Ultragenyx (RARE) Q2 2026 Earnings Call Transcript - AOL.com
Ultragenyx (RARE): RTW Investments and Roderick Wong report 7.9% stake - Stock Titan
Ultragenyx awaits two FDA decisions that could boost its stock to $32 from $27. - Pluang
Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $52, Implies 97% Upside - TradingView
Ultragenyx Stock Looks Undervalued Ahead Of Two FDA Decisions (NASDAQ:RARE) - Seeking Alpha
Ultragenyx (RARE): AQR Capital discloses 6.56M-share, 6.66% ownership stake - Stock Titan
Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
1.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):